$AVLN News
Last published 1w ago
- 1w agoAVLNAvalyn to Present at Upcoming Investor ConferencesGlobeNewswireBOSTON, Nov. 03, 2026 (GLOBE NEWSWIRE) -- Avalyn Pharma Inc. (NASDAQ:AVLN), a clinical-stage biopharmaceutical company pioneering inhaled therapies to transform the treatment paradigm of serious, rare respiratory
- 1mo agoAVLNAvalyn Publishes Phase 1 Data Highlighting AP02’s Lung-Targeted Delivery and Encouraging Safety ProfileGlobeNewswireResults validate Avalyn’s approach of delivering established antifibrotic medicines directly to the lungs to maximize local exposure while limiting systemic exposure and improving tolerability Findings support
- 1mo agoAVLNAvalyn Appoints Robert J. Meyer, MD, to its Board of DirectorsGlobeNewswireBOSTON, Sept. 16, 2026 (GLOBE NEWSWIRE) -- Avalyn Pharma Inc. (NASDAQ:AVLN) ("Avalyn" or the "Company"), a clinical-stage biopharmaceutical company pioneering inhaled therapies to transform the
- 2mo agoAVLNAvalyn to Participate in the Morgan Stanley 24th Annual Global Healthcare ConferenceGlobeNewswireBOSTON, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Avalyn Pharma Inc. (NASDAQ:AVLN), a clinical-stage biopharmaceutical company pioneering inhaled therapies to transform the treatment paradigm of serious, rare respiratory
- 2mo agoAVLNAvalyn Presents New Data at ERS Congress 2026 Supporting AP01 Lung Distribution and Patient-Centered Trial Design in Pulmonary FibrosisGlobeNewswireIn silico modeling predicts robust AP01 distribution in healthy and fibrotic lungs, even in severe disease Patient survey findings suggest that clear communication, transparent discussions of potential benefits and
- 2mo agoAVLNAvalyn Announces Multiple Presentations at the European Respiratory Society International Congress 2026GlobeNewswireBOSTON, Aug. 24, 2026 (GLOBE NEWSWIRE) -- Avalyn Pharma Inc. (NASDAQ:AVLN), a clinical-stage biopharmaceutical company pioneering inhaled therapies to transform the treatment paradigm of serious, rare respiratory
- 3mo agoAVLNAvalyn Reports Second Quarter 2026 Financial Results and Recent Business HighlightsGlobeNewswireCompleted enrollment of MIST global Phase 2b trial of AP01 with 398 patients; topline data expected in the second half of 2027 Two abstracts accepted for presentation at the European Respiratory Society (ERS) Congress,
- 4mo agoAVLNAvalyn Completes Target Enrollment in Phase 2b MIST Trial of AP01 (Inhaled Pirfenidone) for Patients with Progressive Pulmonary FibrosisGlobeNewswireBOSTON, June 17, 2026 (GLOBE NEWSWIRE) -- Avalyn Pharma Inc. (NASDAQ:AVLN) (Avalyn or the Company), a clinical-stage biopharmaceutical company pioneering inhaled therapies to transform the treatment paradigm of
- 5mo agoAVLNAvalyn Reports First Quarter 2026 Financial Results and Recent Business HighlightsGlobeNewswireOn track to complete enrollment of MIST Phase 2b trial of AP01 in progressive pulmonary fibrosis (PPF) in mid-2026, with newly presented long term open-label extension clinical data that support favorable tolerability
- 5mo agoAVLNAvalyn to Participate in the Jefferies Global Healthcare ConferenceGlobeNewswireBOSTON, May 27, 2026 (GLOBE NEWSWIRE) -- Avalyn Pharma Inc. (NASDAQ:AVLN), a clinical-stage biopharmaceutical company pioneering inhaled therapies to transform the treatment paradigm of serious, rare respiratory
- 5mo agoAVLNAvalyn Announces Additional Long-term Data on AP01, Inhaled Pirfenidone, for the Treatment of Pulmonary Fibrosis to be Presented at the European Alliance of Associations for Rheumatology 2026GlobeNewswireBOSTON, May 21, 2026 (GLOBE NEWSWIRE) -- Avalyn Pharma Inc. (NASDAQ:AVLN), a clinical-stage biopharmaceutical company pioneering inhaled therapies to transform the treatment paradigm of serious, rare respiratory
- 6mo agoAVLNAvalyn to Present Patient-Centered Research on AP01 Delivery and Supportive Care Experiences at American Thoracic Society 2026 International ConferenceGlobeNewswireBOSTON, May 05, 2026 (GLOBE NEWSWIRE) -- Avalyn Pharma Inc. (NASDAQ:AVLN), a clinical-stage biopharmaceutical company pioneering inhaled therapies to transform the treatment paradigm of serious, rare respiratory
- 6mo agoAKTSAVLNTwo River and Vida Ventures Extend Track Record of Company Creation and Value Realization Following the Candid Therapeutics' Acquisition by UCBBusiness WireTwo River, LLC ("Two River") and Vida Ventures ("Vida"), both part of the Bellco Health ecosystem, today acknowledged the announced acquisition of Candid Therapeutics ("Candid"), a privately held clinical-stage
- 6mo agoAVLNAvalyn Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional SharesGlobeNewswireBOSTON, May 01, 2026 (GLOBE NEWSWIRE) -- Avalyn Pharma Inc. (NASDAQ:AVLN), a clinical-stage biopharmaceutical company pioneering inhaled therapies to transform the treatment paradigm of serious, rare respiratory
- 6mo agoAVLNAvalyn Announces Pricing of Upsized Initial Public OfferingGlobeNewswireBOSTON, April 29, 2026 (GLOBE NEWSWIRE) -- Avalyn Pharma Inc. (NASDAQ:AVLN) ("Avalyn"), a clinical-stage biopharmaceutical company pioneering inhaled therapies to transform the treatment paradigm of serious, rare
- 6mo agoAVLNAvalyn Strengthens Leadership Team to Support Long-Term Growth with Appointments of Industry Leaders Adam Golden and Frank SalisburyGlobeNewswireBOSTON, April 27, 2026 (GLOBE NEWSWIRE) -- Avalyn Pharma Inc., a clinical-stage biopharmaceutical company pioneering inhaled therapies to transform the treatment paradigm for serious, rare respiratory diseases, today